Xencor Stock News

Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and auto

Xencor, Inc. (NASDAQ:XNCR) CMO Allen Yang sold 3,664 shares of the company’s stock in a transaction that occurred on Friday, December 17th. The shares were sold at an average price of $36.62, for a total value of $134,175.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available […]

Brokerages predict that Xencor, Inc. (NASDAQ:XNCR) will announce sales of $94.44 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Xencors earnings, with estimates ranging from $17.40 million to $115.60 million. Xencor posted sales of $41.85 million during the same quarter last year, which suggests a positive year-over-year growth []

GSK Singapore is contracted to supply the Government of Singapore with additional doses of sotrovimab, following the first purchase placed by the Ministry of Health (MOH) in June 2021 Sotrovimab was approved by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization in June 2021 SINGAPORE , Dec. 7, 2021 /PRNewswire/ -- GlaxoSmithKline Singapore announced an agreement with the Government of Singapore to supply additional doses of sotrovimab. Sotrovimab is an investigational single-dose monoclonal antibody developed in partnership with Vir Biotechnology, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. This follows the initial purchase agreement signed between GSK Singapore and the government in June 2021 . Priya Kudva Menon , VP and General Manager, GSK Singapore, said: "As we move into the endemic stage of COVID-19 in Singapore , it is clear that multiple treatment options are needed to manage the impact of this virus on people and communities, in addition to vaccinations and other preventative measures.

Analysts expect Xencor, Inc. (NASDAQ:XNCR) to report earnings of $0.17 per share for the current quarter, according to Zacks. Four analysts have issued estimates for Xencor’s earnings, with estimates ranging from ($0.75) to $0.89. Xencor posted earnings per share of ($0.24) in the same quarter last year, which suggests a positive year over year growth […]

MorphoSys AG found using ticker (MOR) now have 2 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 21.86 and 11.92 calculating the mean target price we have 16.89. Given that the stocks previous close was at 9.72 this indicates there is a potential upside of 73.8%. The 50 day moving average now sits at 11.49 and the 200 day MA is 17.78. The company has a market cap of $1,411m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="MOR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.

Invesco Ltd. boosted its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 7.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 535,717 shares of the biopharmaceutical companys stock after purchasing an additional 35,436 shares during the period. Invesco Ltd.s holdings in Xencor were []

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus recommendation of Buy by the ten ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year []

Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR ) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain. It uses Xencor''s XmAb Immune Inhibitor Fc Domain to target FcγRIIb, a receptor that inhibits the function … Full story available on Benzinga.com

MONROVIA, Calif., HONG KONG & BOSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (Zenas), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufact

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and auto